Menopause — MCQs
On this page
What is the most common symptom treated with hormone therapy (HT) in menopausal women?
Menopause is defined as?
Which of the following is not a common symptom of menopause?
How is MENOPAUSE diagnosed?
What is the primary use of Tibolone in post-menopausal women?
What is the primary cancer risk associated with the simultaneous administration of estrogen and progesterone in hormone replacement therapy?
What is one of the benefits of hormone replacement therapy (HRT) in postmenopausal women?
What does HT stand for in the context of menopausal treatment?
What is the primary hormonal cause of hot flushes experienced during menopause?
Which among the following is an absolute contraindication of Hormone replacement therapy?
Menopause Indian Medical PG Practice Questions and MCQs
Question 91: What is the most common symptom treated with hormone therapy (HT) in menopausal women?
- A. Endometriosis
- B. Uterine bleeding
- C. Hot flashes (Correct Answer)
- D. Breast cancer
Explanation: ***Hot flashes*** - **Vasomotor symptoms**, including hot flashes and night sweats, are the most frequent and bothersome symptoms experienced by menopausal women, leading them to seek medical attention and hormone therapy. - HT is highly effective in reducing the frequency and severity of hot flashes by stabilizing **thermoregulation** in the hypothalamus. *Breast cancer* - **Breast cancer** is a potential risk associated with hormone therapy, particularly with combined estrogen-progestin therapy, not a symptom treated by HT. - Women with a history of breast cancer or those at high risk are generally advised against HT due to this increased risk. *Endometriosis* - While **estrogen-dependent diseases** like endometriosis can be aggravated by HRT, endometriosis itself is a condition that typically improves after menopause. - HT is not used to treat endometriosis; in certain cases, it might be used to manage menopausal symptoms in women with a history of endometriosis after specific surgical interventions. *Uterine bleeding* - **Uterine bleeding** can be a side effect of hormone therapy, especially when progestin is not adequately balanced with estrogen in women with a uterus. - Abnormal uterine bleeding is a symptom that requires investigation to rule out other causes, and it is not a primary symptom treated by HT.
Question 92: Menopause is defined as?
- A. Presence of hot flashes
- B. Cessation of menses for one year (Correct Answer)
- C. Cessation of menses for six months
- D. Cessation of menses for two years
Explanation: ***Cessation of menses for one year*** - Menopause is clinically defined as **12 consecutive months of amenorrhea** (absence of menstruation) in women of appropriate age. - This definition is crucial for distinguishing menopause from **perimenopause**, where menstrual cycles can be irregular. *Presence of hot flashes* - **Hot flashes** are a common symptom of menopause and perimenopause, but their presence *alone* does not define menopause. - Many women experience hot flashes for years **before** or after the official menopausal transition. *Cessation of menses for six months* - A 6-month period of amenorrhea is **insufficient** to diagnose menopause, as menstrual cycles can become irregular during perimenopause and then resume. - This duration might be indicative of **oligomenorrhea** or other gynecological issues, not necessarily permanent ovarian failure. *Cessation of menses for two years* - While a 2-year cessation of menses would certainly indicate menopause, the generally accepted and more precise clinical definition is **one year (12 months)**. - Using a 2-year cessation would **delay diagnosis** unnecessarily for a significant period.
Question 93: Which of the following is not a common symptom of menopause?
- A. Night sweats
- B. Decreased libido
- C. Intermittent hypotension (Correct Answer)
- D. Hot flushes
Explanation: ***Intermittent hypotension*** - **Intermittent hypotension** is not primarily associated with menopause; rather, **hypertension** and increased cardiovascular risk can be observed after menopause due to hormonal changes - While many bodily changes occur during menopause, fluctuating decreases in blood pressure are not typical hallmark symptoms - Estrogen loss may actually contribute to increased blood pressure through effects on vascular function and lipid metabolism *Night sweats* - **Night sweats** are a common **vasomotor symptom** during menopause, often accompanying hot flashes - Caused by hormonal fluctuations, particularly drops in **estrogen levels**, affecting the body's **thermoregulation** - Can significantly disrupt sleep and affect quality of life *Decreased libido* - A **decrease in libido** is a frequently reported symptom during menopause, attributed to lower **estrogen** and **testosterone** levels - Hormonal changes can lead to **vaginal dryness** and discomfort during intercourse, further contributing to reduced sexual desire - Psychological factors and sleep disturbances may also contribute *Hot flushes* - **Hot flushes** (hot flashes) are the most characteristic **vasomotor symptom** of menopause, experienced by 60-80% of women - Involve sudden sensations of heat, sweating, and flushed skin, often triggered by hormonal shifts, specifically fluctuating **estrogen** - Typically last 30 seconds to several minutes and may occur multiple times daily
Question 94: How is MENOPAUSE diagnosed?
- A. Estradiol levels <20 pg/ml
- B. Progesterone levels <40 ng/dl
- C. FSH levels >40 IU/L (Correct Answer)
- D. LH levels > 20 IU/L
Explanation: ***FSH levels >40 IU/L*** - **Menopause is primarily a clinical diagnosis** based on 12 consecutive months of amenorrhea in women over 45 years with appropriate symptoms. - When laboratory confirmation is needed (e.g., women <45 years, unclear cases), a **persistently elevated FSH level >40 IU/L** is the most reliable hormonal marker. - This elevation reflects **lack of ovarian follicular activity** and decreased estrogen production, leading to reduced negative feedback on the pituitary. - **Note:** FSH can fluctuate during perimenopause, so a single measurement may not be definitive. *Estradiol levels <20 pg/ml* - While **low estradiol levels** are characteristic of menopause due to ovarian failure, they are not the primary diagnostic marker. - Estradiol levels **fluctuate significantly** during the perimenopausal transition and are less reliable than FSH. - Not routinely used for diagnosis. *Progesterone levels <40 ng/dl* - **Progesterone levels** are typically low after cessation of ovulation. - However, progesterone measurement is **not considered a diagnostic criterion** for menopause. - Less useful than FSH for diagnostic purposes. *LH levels > 20 IU/L* - **LH levels** do increase during menopause due to loss of negative feedback from ovarian hormones. - However, **FSH elevation is more consistent and of higher magnitude**, making it the preferred hormonal marker when laboratory testing is indicated. - LH cutoff of >20 IU/L is lower than typical diagnostic thresholds.
Question 95: What is the primary use of Tibolone in post-menopausal women?
- A. Hormone replacement therapy (Correct Answer)
- B. Treatment of fibroids
- C. Management of endometriosis
- D. Treatment of anovulatory infertility
Explanation: ***Correct: Hormone replacement therapy*** - **Tibolone** is a synthetic steroid with estrogenic, progestogenic, and weak androgenic properties, primarily used to alleviate **menopausal symptoms** such as hot flashes, vaginal dryness, and mood disturbances. - It serves as an alternative to conventional **hormone replacement therapy (HRT)**, offering symptomatic relief and preventing **osteoporosis** in post-menopausal women. *Incorrect: Treatment of fibroids* - **Fibroids** are benign uterine growths that typically respond to treatments that reduce estrogen levels or directly target the fibroid tissue. Tibolone, with its estrogenic activity, is generally **not used** for fibroid treatment and could potentially exacerbate their growth. - Common treatments for fibroids include GnRH agonists, uterine artery embolization, or surgical removal, none of which is tibolone. *Incorrect: Management of endometriosis* - **Endometriosis** is a condition where endometrial-like tissue grows outside the uterus, and its management often involves suppressing ovarian function to reduce estrogen levels, which fuels its growth. Tibolone's estrogenic effects mean it is generally **contraindicated** in active endometriosis. - Treatments often include GnRH agonists, progesterone-only therapies, or surgery to remove endometrial implants. *Incorrect: Treatment of anovulatory infertility* - **Anovulatory infertility** is characterized by irregular or absent ovulation, often treated with medications to induce ovulation. Tibolone is a steroid that can **suppress ovulation** and is therefore not used to promote conception. - Fertility treatments typically involve clomiphene citrate, letrozole, or gonadotropins to stimulate ovulation.
Question 96: What is the primary cancer risk associated with the simultaneous administration of estrogen and progesterone in hormone replacement therapy?
- A. Breast cancer (Correct Answer)
- B. Cervical cancer
- C. Both a and b
- D. Ovarian cancer
Explanation: ***Breast cancer*** - **Combined estrogen and progesterone** in hormone replacement therapy (HRT) has been linked to an increased risk of **breast cancer**, particularly with long-term use. - The addition of progesterone to estrogen helps mitigate the risk of **endometrial cancer** but does not eliminate the breast cancer risk, and may in fact contribute to it. *Cervical cancer* - **Cervical cancer** is primarily caused by persistent infection with **high-risk human papillomavirus (HPV)**. - There is no direct evidence to suggest that combined estrogen and progesterone HRT significantly increases the risk of cervical cancer. *Both a and b* - While HRT with combined estrogen and progesterone increases the risk of **breast cancer**, it does not significantly increase the risk of **cervical cancer**. - Attributing an increased risk for both conditions due to combined HRT is inaccurate based on current evidence. *Ovarian cancer* - Some studies suggest a possible **slight increase in ovarian cancer risk** with combined HRT, but this finding is **inconsistent** across research and the risk is generally considered to be small if present. - The most significant and well-established cancer risk with combined HRT is **breast cancer**.
Question 97: What is one of the benefits of hormone replacement therapy (HRT) in postmenopausal women?
- A. Bone density (Correct Answer)
- B. Coronary artery disease
- C. Endometrial cancer
- D. Dementia
Explanation: ***Bone density*** - HRT with estrogen has been shown to **prevent bone loss** and reduce the risk of **osteoporotic fractures** in postmenopausal women. - Estrogen plays a crucial role in maintaining **bone mineral density** by inhibiting osteoclast activity. *Dementia* - While earlier observational studies suggested a benefit, large randomized controlled trials like the **Women's Health Initiative (WHI)** found no protective effect of HRT on **dementia** and even showed an increased risk in older women initiating HRT. - The use of HRT is **not recommended for the prevention or treatment of dementia.** *Coronary artery disease* - The WHI study demonstrated that combined estrogen-progestin HRT actually **increased the risk of coronary artery disease** events, especially in older women initiating HRT years after menopause. - HRT is **not indicated for the primary or secondary prevention of cardiovascular disease**. *Endometrial cancer* - Unopposed estrogen therapy in women with an intact uterus **increases the risk of endometrial hyperplasia and cancer**. - To counteract this risk, **progestin is added** to estrogen therapy for women with a uterus to protect the endometrium.
Question 98: What does HT stand for in the context of menopausal treatment?
- A. Hormone Therapy (Correct Answer)
- B. Hysterectomy Treatment
- C. Hormonal Transplant
- D. Hyperthermia Therapy
Explanation: ***Hormone Therapy*** - **HT** is the widely accepted abbreviation for **Hormone Therapy** in the context of menopausal treatment. - This treatment involves administering **estrogen** and/or **progestin** to alleviate menopausal symptoms such as hot flashes, vaginal dryness, and bone loss. - HT is the standard terminology used in current medical practice and literature. *Hysterectomy Treatment* - While hysterectomy is a gynecological procedure, "Hysterectomy Treatment" is not abbreviated as HT in medical terminology. - Hysterectomy refers to surgical removal of the uterus, not a treatment abbreviation. *Hormonal Transplant* - This is not a recognized medical term or treatment modality. - "Hormonal Transplant" is not used in clinical practice and does not abbreviate to HT. *Hyperthermia Therapy* - While this could theoretically abbreviate to HT, it refers to a cancer treatment using heat, not a menopausal treatment. - In the specific context of menopausal treatment, HT exclusively refers to Hormone Therapy.
Question 99: What is the primary hormonal cause of hot flushes experienced during menopause?
- A. Increased noradrenaline with normal estrogen levels
- B. Increased noradrenaline
- C. Decreased estrogen levels (Correct Answer)
- D. Both increased noradrenaline and decreased estrogen levels
Explanation: ***Decreased estrogen levels*** - **Decreased estrogen** is the primary hormonal change during menopause, leading to thermoregulatory dysfunction in the hypothalamus. - This hormonal imbalance causes the **vasomotor symptoms** like hot flushes and night sweats. *Increased noradrenaline* - While **noradrenaline** (norepinephrine) is involved in thermoregulation, its increase is a **secondary event** triggered by the initial estrogen deficiency, not the primary cause. - Increased noradrenaline can exacerbate the **vasodilation** and heat dissipation experienced during a hot flush. *Increased noradrenaline with normal estrogen levels* - This option is incorrect because hot flushes are characteristic of menopause, which is defined by **decreased estrogen levels**. - **Normal estrogen levels** would typically prevent the severe thermoregulatory instability that causes hot flushes. *Both increased noradrenaline and decreased estrogen levels* - Although both factors are involved, the question asks for the **primary hormonal cause**. **Decreased estrogen** initiates the cascade of events, including the subsequent alteration of neurotransmitter levels like noradrenaline. - Noradrenaline's role is more of a **mediator** in the physiological response to the primary estrogen deficiency.
Question 100: Which among the following is an absolute contraindication of Hormone replacement therapy?
- A. Endometriosis
- B. Heart disease
- C. Breast carcinoma (Correct Answer)
- D. Osteoarthritis
Explanation: ### Breast carcinoma - Hormone replacement therapy (HRT) is **contraindicated** in breast carcinoma because many breast cancers are **estrogen-receptor positive**, meaning estrogen can stimulate their growth [1]. - Using HRT in patients with a history of breast cancer significantly increases the risk of **recurrence** or **progression** of the disease [1]. *Endometriosis* - Endometriosis is not an **absolute contraindication**; HRT can sometimes be used in women with a history of endometriosis, especially if a hysterectomy and bilateral oophorectomy have been performed. - However, unopposed estrogen therapy might **exacerbate** remaining endometrial implants, so a combined estrogen-progestin regimen is typically preferred [1]. *Heart disease* - While HRT has been shown to have **risks** in women with established coronary heart disease, it is not an absolute contraindication for all forms of heart disease. - The **Women's Health Initiative study** demonstrated increased cardiovascular events in older women initiating HRT, but current guidelines suggest that timing of initiation is crucial and benefits may outweigh risks for younger postmenopausal women. *Osteoarthritis* - Osteoarthritis is **not a contraindication** to HRT; in fact, some studies suggest that estrogen may have protective effects on cartilage [2]. - HRT is neither a treatment nor a contraindication for osteoarthritis and does not significantly impact its progression or severity [2].
Practice by Chapter
Physiology of Menopause
Practice Questions
Perimenopausal Transition
Practice Questions
Menopausal Symptoms and Management
Practice Questions
Hormone Replacement Therapy
Practice Questions
Non-hormonal Management Options
Practice Questions
Osteoporosis Prevention and Management
Practice Questions
Cardiovascular Health in Menopause
Practice Questions
Urogenital Atrophy
Practice Questions
Psychological Aspects of Menopause
Practice Questions
Premature Menopause
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free